2022 World Conference on Lung Cancer (ePosters)-EP02.04-010. Clinical Outcomes After Neoadjuvant Tislelizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC: A Retrospective Study

EP02.04-010. Clinical Outcomes After Neoadjuvant Tislelizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC: A Retrospective Study

Back to course

Pdf Summary

A retrospective study was conducted to evaluate the effectiveness and safety of neoadjuvant tislelizumab, a monoclonal antibody, combined with chemotherapy in patients with resectable stage IIIA-B non-small-cell lung cancer (NSCLC). The study included 19 patients who underwent surgery after receiving the neoadjuvant treatment. The primary endpoints of the study were the clinical down-staging rate and major pathological response (MPR). The secondary endpoints included pathological complete response (pCR) and surgical outcomes.<br /><br />The results showed that the down-staging rate and MPR were both 78.95%. This indicated that a majority of patients achieved a deep pathological response after receiving the neoadjuvant treatment. The study also found that 52.63% of patients achieved a pCR, and the R0 resection rate was 100%. There were no deaths at 90 days after surgery, and 100% of the surgeries were performed using video-assisted thoracic surgery (VATS).<br /><br />The study concluded that neoadjuvant tislelizumab plus chemotherapy may be an effective treatment option for resectable stage IIIA-B NSCLC, as it was shown to down-stage tumors and achieve pathological remission without affecting the feasibility of surgery. The study also suggested that 3-4 cycles of neoadjuvant therapy may be necessary for clinical down-staging, while 2 cycles may be sufficient for tumor pathological remission. The researchers emphasized the need for further prospective studies to validate these findings.<br /><br />Overall, the study provides evidence for the efficacy and safety of neoadjuvant tislelizumab plus chemotherapy in patients with resectable stage IIIA-B NSCLC. This treatment approach may hold promise for improving outcomes in these patients.

Asset Subtitle

Xiangyang Cheng, China

Meta Tag

Speaker Xiangyang Cheng, China

Topic Early Stage Non-small Cell Lung Cancer - Systemic Therapy

Keywords

retrospective study

neoadjuvant tislelizumab

chemotherapy

resectable stage IIIA-B NSCLC

clinical down-staging rate

major pathological response

surgical outcomes

video-assisted thoracic surgery

pathological remission

prospective studies